Pancreatic Neuroendocrine Neoplasm
Conditions
Keywords
EGFR, nimotuzumab, Pancreatic Neuroendocrine Neoplasm
Brief summary
The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
Detailed description
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with various types of cancer with EGFR overexpression. The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
Interventions
DRUGNimotuzumab
nimotuzumab 200mg/week
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with well and moderately differentiated with evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent. 2. Overexpression of EGFR in tumor tissue sample from tumor biopsy or prior primary tumor resection. Therefore availability of paraffin-embedding tumor tissue sample is needed. 3. Documented progression of the disease by CT scan, MRI, or Octreoscan within 12 months prior to baseline. 4. Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy. 5. Male or female, 18 years of age or older. 6. ECOG performance status less than 2. 7. Life expectancy greater than 12 weeks. 8. The definitions of minimum adequacy for organ function required prior to study entry are as follows. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) \< 2.5 x upper limit of normal (ULN), or AST and ALT \< 5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin \< 1.5 x ULN Serum albumin \> 3.0 g/dL Absolute neutrophil count (ANC) \> 1500/L Hemoglobin \> 9.0 g/dL Creatinin clearance \< 40 mL/min 9. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion criteria
1. Active second primary malignancy or history of second primary malignancy. 2. Current treatment on another clinical trial. 3. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus. 4. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to randomization. 5. Pathological confirmed to be poor differentiated tumor of pancreatic neuroendocrine neoplasms. 6. Patients who are unwilling or unable to comply with study procedures. 7. Prior targeted treatment on EGFR. 8. Low expression or absence of EGFR in tumor tissue sample from tumor biopsy or prior primary tumor resection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate (ORR) | Baseline to 6 months | Overall Response rate was defined as the proportion of patients with a best overall response of complete response or partial response, based on investigator's assessment as per RECIST criteria version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | Baseline to 6 months | Disease control rate was defined as the proportion of patients with a best overall response of Complete Response, Partial response, or Stable disease, based on the investigator's assessment per RECIST version 1.1. |
| Progression free survival (PFS) | Patients will be followed until disease progression, estimating around 12months | — |
| Overall survival (OS) | Patients will be followed until disease progression, estimating around 12months | — |
Countries
China
Outcome results
None listed